N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.39 CNY -2.41% Market Closed
Updated: May 25, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

9.5B
-14%
Assets
Growth Rates:
1 Year
-5%
3 Years
+23%
5 Years
+180%
7 Years
+525%
10 Years
-
3.7B
-13%
Liabilities
Growth Rates:
1 Year
-3%
3 Years
-7%
5 Years
+279%
7 Years
+1 689%
10 Years
-
5.8B
-15%
Equity
Growth Rates:
1 Year
-6%
3 Years
+56%
5 Years
+140%
7 Years
+341%
10 Years
-

Balance Sheet Decomposition
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

9.5B
Assets
3.7B
Liabilities
9.5B
Assets
3.7B
Liabilities
Current Assets 7.3B
Cash & Short-Term Investments 1.6B
Receivables 1.1B
Other Current Assets 4.5B
Non-Current Assets 2.3B
Long-Term Investments 72.5m
PP&E 1.2B
Intangibles 594.8m
Other Non-Current Assets 349.6m
Current Liabilities 3.1B
Accounts Payable 537.7m
Accrued Liabilities 294.8m
Short-Term Debt 1.6B
Other Current Liabilities 686.9m
Non-Current Liabilities 636m
Long-Term Debt 525.6m
Other Non-Current Liabilities 110.4m

Balance Sheet
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
594
433
266
73
435
249
473
435
303
894
Cash
0
0
0
0
0
0
0
435
303
894
Cash Equivalents
594
432
266
73
434
248
473
0
0
0
Short-Term Investments
229
180
0
520
95
67
845
243
1
682
Total Receivables
68
66
104
292
306
513
936
1 074
1 224
1 138
Accounts Receivables
53
61
76
230
176
389
783
837
952
751
Other Receivables
15
5
28
62
130
124
153
237
272
387
Inventory
326
282
672
1 294
1 952
3 274
4 457
4 894
5 616
4 158
Other Current Assets
2
5
12
13
51
186
57
283
1 150
389
Total Current Assets
1 220
966
1 053
2 192
2 838
4 289
6 768
6 930
8 294
7 262
PP&E Net
296
305
415
449
480
523
649
910
1 214
1 246
PP&E Gross
296
305
415
449
480
523
649
910
1 214
1 246
Accumulated Depreciation
46
65
359
398
436
475
543
613
706
828
Intangible Assets
16
17
46
45
74
125
159
200
212
467
Goodwill
0
0
0
0
0
126
118
115
125
128
Long-Term Investments
4
3
3
3
4
1
3
26
62
72
Other Long-Term Assets
5
7
7
7
7
15
23
36
103
350
Other Assets
0
0
0
0
0
126
118
115
125
128
Total Assets
1 540
N/A
1 297
-16%
1 523
+17%
2 695
+77%
3 402
+26%
5 078
+49%
7 720
+52%
8 217
+6%
10 010
+22%
9 524
-5%
Liabilities
Accounts Payable
15
27
14
90
309
290
412
434
504
538
Accrued Liabilities
16
10
14
18
22
50
47
65
88
295
Short-Term Debt
418
101
120
443
528
1 570
2 223
1 607
1 960
1 567
Current Portion of Long-Term Debt
0
2
0
0
0
0
0
0
0
505
Other Current Liabilities
37
43
25
56
89
124
124
161
153
181
Total Current Liabilities
486
183
173
607
947
2 033
2 806
2 266
2 705
3 086
Long-Term Debt
0
0
0
0
0
6
1 132
481
1 013
526
Deferred Income Tax
0
0
0
0
0
0
0
1
40
37
Minority Interest
0
0
0
0
0
38
22
25
3
3
Other Liabilities
22
22
36
36
34
35
38
66
85
77
Total Liabilities
508
N/A
205
-60%
208
+2%
643
+209%
981
+53%
2 112
+115%
3 998
+89%
2 839
-29%
3 839
+35%
3 722
-3%
Equity
Common Stock
360
360
360
424
552
719
934
1 244
1 617
1 617
Retained Earnings
416
476
697
1 012
1 373
1 900
2 494
3 136
3 930
3 556
Additional Paid In Capital
257
257
257
617
513
356
158
988
604
601
Treasury Stock
0
0
0
0
20
17
14
47
33
28
Other Equity
0
0
1
1
4
9
151
58
53
56
Total Equity
1 032
N/A
1 093
+6%
1 315
+20%
2 052
+56%
2 421
+18%
2 967
+23%
3 722
+25%
5 378
+44%
6 171
+15%
5 802
-6%
Total Liabilities & Equity
1 540
N/A
1 297
-16%
1 523
+17%
2 695
+77%
3 402
+26%
5 078
+49%
7 720
+52%
8 217
+6%
10 010
+22%
9 524
-5%
Shares Outstanding
Common Shares Outstanding
791
791
791
930
930
931
933
1 613
1 613
1 613

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 140,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.